Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 6, 2013, Pages

  Kelly Cobbs, Aisha I ^a   Prakash, Roshini ^b,c   Li, Weiguo ^a   Pillai, Bindu ^b,c   Hafez, Sherif ^b   Coucha, Maha ^a   Johnson, Maribeth H ^b   Ogbi, Safia N ^a   Fagan, Susan C ^b,c   Ergul, Adviye ^a,b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

5,10,15,20 tetrakis(4 sulfonatophenyl)prophyrinato iron (III); Curcumin; Minocycline; Nuclear factor B; Vascular protection

Indexed keywords

CURCUMIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINOCYCLINE; PEROXYNITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT;

ANIMALS; CURCUMIN; DIABETES MELLITUS, TYPE 2; EDEMA; HEMORRHAGE; INFARCTION, MIDDLE CEREBRAL ARTERY; LOCOMOTION; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; METALLOPORPHYRINS; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PEROXYNITROUS ACID; RATS; RATS, MUTANT STRAINS; RATS, WISTAR;

EID: 84878547802     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00720.2012     Document Type: Article

References (61)

1. Alvarez-Sabin J, Molina CA, Ribo M, Arenillas JF, Montaner J, Huertas R, Santamarina E, Rubiera M. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke 35: 2493-2498, 2004.
2. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33: 2711-2717, 2002.
3. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20: 1681-1689, 2000.
4. Banerjee C, Moon YP, Paik MC, Rundek T, Mora-McLaughlin C, Vieira JR, Sacco RL, Elkind MS. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan study. Stroke 43: 1212-1217, 2012.
5. Beauchamp MH, Sennlaub F, Speranza G, Gobeil F Jr, Checchin D, Kermorvant-Duchemin E, Abran D, Hardy P, Lachapelle P, Varma DR, Chemtob S. Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. Free Radic Biol Med 37: 1885-1894, 2004.
6. Bruno A, Kent TA, Coull BM, Shankar RR, Saha C, Becker KJ, Kissela BM, Williams LS. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 39: 384-389, 2008.
7. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 (online). http://www.cdc.gov/diabetes/ pubs/pdf/ndfs_2011.pdf [31 January 2013].
8. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32: 2393-2404, 2007.
9. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108: 1527-1532, 2003.
10. Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, Petteway SR Jr, Arora V. Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model. Exp Transl Stroke Med 3: 10, 2011.
11. del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, Wang X, Hosomi N, Mabuchi T, Koziol JA. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab 32: 919-932, 2012.
12. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 38: 646-651, 2007.
13. Dohare P, Garg P, Jain V, Nath C, Ray M. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res 193: 289-297, 2008.
14. Duplain H, Sartori C, Dessen P, Jayet PY, Schwab M, Bloch J, Nicod P, Scherrer U. Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice. J Physiol 586: 4011-4016, 2008.
15. Elgebaly MM, Kelly A, Harris AK, Elewa H, Portik-Dobos V, Ketsawatsomkron P, Marrero M, Ergul A. Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1. Can J Physiol Pharmacol 86: 358-364, 2008.
16. Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, Bruno A, Fagan SC, Ergul A. Neurovascular injury in acute hyperglycemia and diabetes: a comparative analysis in experimental stroke. Transl Stroke Res 2: 391-398, 2011.
17. Elgebaly MM, Prakash R, Li W, Ogbi S, Johnson MH, Mezzetti EM, Fagan SC, Ergul A. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab 30: 1928-1938, 2010.
18. Ergul A, Elgebaly MM, Middlemore ML, Li W, Elewa H, Switzer JA, Hall C, Kozak A, Fagan SC. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 7: 33, 2007.
19. Fagan SC, Garcia JH. Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator. Pharmacotherapy 19: 139-142, 1999.
20. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 41: 2283-2287, 2010.
21. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217: 855-857, 1982.
22. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375, 2003.
23. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842: 92-100, 1999.
24. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL Jr, del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 35: 998-1004, 2004.
25. Goto Y. [What do spontaneously diabetic animals suggest?]. Nihon Naika Gakkai Zasshi 77: 1177-1185, 1988.
26. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 119: 85-90, 1976.
27. Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, Fagan SC, Ergul A. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54: 2638-2644, 2005.
28. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
29. Ishrat T, Sayeed I, Atif F, Stein DG. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res 1257: 94-101, 2009.
30. Jian Liu K, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39: 71-80, 2005.
31. Jiang J, Wang W, Sun YJ, Hu M, Li F, Zhu DY. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 561: 54-62, 2007.
32. Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke 40: 3804-3809, 2009.
33. Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke 38: 1044-1049, 2007.
34. Kelly-Cobbs AI, Prakash R, Coucha M, Knight RA, Li W, Ogbi SN, Johnson M, Ergul A. Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone. J Pharmacol Exp Ther 342: 407-415, 2012.
35. Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 200: 38-49, 2006.
36. King MD, McCracken DJ, Wade FM, Meiler SE, Alleyne CH Jr, Dhandapani KM. Attenuation of hematoma size and neurological injury with curcumin following intracerebral hemorrhage in mice. J Neurosurg 115: 116-123, 2011.
37. Li W, Prakash R, Kelly-Cobbs AI, Ogbi S, Kozak A, El-Remessy AB, Schreihofer DA, Fagan SC, Ergul A. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 59: 228-235, 2010.
38. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91, 1989.
39. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 7: 56, 2006.
40. Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 20: 268-287, 2004.
41. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 27: 435-451, 2007.
42. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T, Tamatani T, Miyasaka M, Kogure K. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 656: 344-352, 1994.
43. McColl BW, Rose N, Robson FH, Rothwell NJ, Lawrence CB. Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab 30: 267-272, 2009.
44. Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK, Currie MG, Salvemini D. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem 273: 15646-15653, 1998.
45. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581-1587, 1995.
46. Peters A, Laffel L. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care 34: 2477-2485, 2011.
47. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone F. Matrix metalloproteinase expression increases after cerebral focal ischemia. Stroke 29: 1020-1030, 1997.
48. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 22: E4, 2007.
49. Salvemini D, Wang ZQ, Stern MK, Currie MG, Misko TP. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Natl Acad Sci USA 95: 2659-2663, 1998.
50. Schildknecht S, Pape R, Muller N, Robotta M, Marquardt A, Burkle A, Drescher M, Leist M. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 286: 4991-5002, 2011.
51. Sharma SS, Dhar A, Kaundal RK. FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils. Pharmacol Res 55: 335-342, 2007.
52. Sharma SS, Munusamy S, Thiyagarajan M, Kaul CL. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia. J Neurosurg 101: 669-675, 2004.
53. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14, 2010.
54. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24: 2182-2190, 2004.
55. Suofu Y, Clark JF, Broderick JP, Kurosawa Y, Wagner KR, Lu A. Matrix metalloproteinase-2 or-9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience 212: 180-189, 2012.
56. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 5: 1732-1739, 2007.
57. Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 74: 969-985, 2004.
58. Xing C, Levchenko T, Guo S, Stins M, Torchilin VP, Lo EH. Delivering minocycline into brain endothelial cells with liposome-based technology. J Cereb Blood Flow Metab 32: 983-988, 2012.
59. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500, 1999.
60. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267-270, 2003.
61. Zhao J, Yu S, Zheng W, Feng G, Luo G, Wang L, Zhao Y. Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Neurochem Res 35: 374-379, 2010.